Drew Ranieri
Stock Analyst at Morgan Stanley
(1.26)
# 3,714
Out of 5,149 analysts
170
Total ratings
45.65%
Success rate
-11.37%
Average return
Main Sectors:
Stocks Rated by Drew Ranieri
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SIBN SI-BONE | Maintains: Overweight | $20 → $23 | $15.34 | +49.93% | 16 | Dec 2, 2025 | |
| GMED Globus Medical | Maintains: Overweight | $70 → $100 | $91.70 | +9.05% | 14 | Dec 2, 2025 | |
| ATEC Alphatec Holdings | Maintains: Equal-Weight | $16 → $21 | $13.02 | +61.29% | 11 | Nov 10, 2025 | |
| ORGO Organogenesis Holdings | Maintains: Equal-Weight | $4 → $6 | $2.87 | +109.06% | 4 | Mar 5, 2025 | |
| SYK Stryker | Upgrades: Overweight | $370 → $445 | $384.59 | +15.71% | 9 | Dec 2, 2024 | |
| IART Integra LifeSciences Holdings | Maintains: Underweight | $24 → $27 | $10.56 | +155.68% | 15 | Jul 15, 2024 | |
| TMCI Treace Medical Concepts | Maintains: Equal-Weight | $5.5 → $8 | $1.57 | +409.55% | 12 | Jul 15, 2024 | |
| STVN Stevanato Group | Maintains: Equal-Weight | $26 → $22 | $14.73 | +49.36% | 16 | Jul 15, 2024 | |
| NPCE NeuroPace | Maintains: Equal-Weight | $9.5 → $8 | $13.83 | -42.15% | 13 | Jul 15, 2024 | |
| OM Outset Medical | Maintains: Equal-Weight | $75 → $83 | $3.48 | +2,270.69% | 10 | Dec 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $38 | $28.67 | +32.54% | 9 | Nov 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $88 → $96 | $65.63 | +46.27% | 10 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $28 → $26 | $13.99 | +85.85% | 8 | May 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $290 → $295 | $174.21 | +69.34% | 2 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $236 → $280 | $122.19 | +129.15% | 5 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $5 | $8.74 | -42.79% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $72 → $70 | $19.03 | +267.84% | 4 | Oct 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $325 → $300 | $497.42 | -39.69% | 6 | Apr 25, 2022 |
SI-BONE
Dec 2, 2025
Maintains: Overweight
Price Target: $20 → $23
Current: $15.34
Upside: +49.93%
Globus Medical
Dec 2, 2025
Maintains: Overweight
Price Target: $70 → $100
Current: $91.70
Upside: +9.05%
Alphatec Holdings
Nov 10, 2025
Maintains: Equal-Weight
Price Target: $16 → $21
Current: $13.02
Upside: +61.29%
Organogenesis Holdings
Mar 5, 2025
Maintains: Equal-Weight
Price Target: $4 → $6
Current: $2.87
Upside: +109.06%
Stryker
Dec 2, 2024
Upgrades: Overweight
Price Target: $370 → $445
Current: $384.59
Upside: +15.71%
Integra LifeSciences Holdings
Jul 15, 2024
Maintains: Underweight
Price Target: $24 → $27
Current: $10.56
Upside: +155.68%
Treace Medical Concepts
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $5.5 → $8
Current: $1.57
Upside: +409.55%
Stevanato Group
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $26 → $22
Current: $14.73
Upside: +49.36%
NeuroPace
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $9.5 → $8
Current: $13.83
Upside: -42.15%
Outset Medical
Dec 4, 2023
Maintains: Equal-Weight
Price Target: $75 → $83
Current: $3.48
Upside: +2,270.69%
Nov 2, 2023
Maintains: Overweight
Price Target: $42 → $38
Current: $28.67
Upside: +32.54%
May 12, 2023
Maintains: Equal-Weight
Price Target: $88 → $96
Current: $65.63
Upside: +46.27%
May 4, 2023
Maintains: Underweight
Price Target: $28 → $26
Current: $13.99
Upside: +85.85%
Feb 3, 2023
Maintains: Overweight
Price Target: $290 → $295
Current: $174.21
Upside: +69.34%
Jan 6, 2023
Maintains: Equal-Weight
Price Target: $236 → $280
Current: $122.19
Upside: +129.15%
Nov 10, 2022
Maintains: Overweight
Price Target: $11 → $5
Current: $8.74
Upside: -42.79%
Oct 11, 2022
Maintains: Overweight
Price Target: $72 → $70
Current: $19.03
Upside: +267.84%
Apr 25, 2022
Maintains: Equal-Weight
Price Target: $325 → $300
Current: $497.42
Upside: -39.69%